<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tirzepatide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tirzepatide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tirzepatide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="138734" href="/d/html/138734.html" rel="external">see "Tirzepatide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F59011471"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Glucagon-Like Peptide-1 Receptor Agonists Safety Update</span>
<span class="collapsible-date">January 2024</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). A preliminary evaluation has not found evidence that the use of these medicines causes suicidal thoughts or actions, but the FDA is continuing to investigate this issue. Patients should not stop taking GLP-1 RAs without consulting their health care provider. Health care providers should monitor for and advise patients using GLP-1 RAs to report new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Fupdate-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type&amp;token=miTanb%2Bz8Mpo90N4aa9rnBvzPyMcyGMouSYn352zIq27XyRAnm%2BDWunTXNDIRGRVPdvEcJ4t0dBZwKHPsWODdcKNBqg8p81GHTpH2D6qQhfyYSllM0BIXdmigC6Atf7BXgPxeZTU1rPJai25j9dr%2BiXxmVJc5lhSTyKtYrSUSj8%3D&amp;TOPIC_ID=138675" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F56830406"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of thyroid C-cell tumors</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.</p>
<p style="text-indent:0em;margin-left:2em;">Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of tirzepatide and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with tirzepatide.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56874964"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mounjaro;</li>
<li>Zepbound</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58872666"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Mounjaro</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56830409"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Glucose-Dependent Insulinotropic Polypeptide (GIP)/Glucagon-Like Peptide (GLP-1) Receptor Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F56848803"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>May require a dose reduction of insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinides) to avoid hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600'])">Ref</a></span>). Use is not recommended in patients with severe GI disease (eg, severe gastroparesis) (has not been studied).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b>
<b>Note:</b> Due to lack of additive glycemic benefit, avoid concomitant use with a dipeptidyl peptidase-4 inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30291106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30291106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Initial: 2.5 mg once weekly for 4 weeks, then increase to 5 mg once weekly. May increase dose in 2.5 mg/week increments every 4 weeks if needed to achieve glycemic goals (maximum weekly dose: 15 mg/week). <b>Note:</b> The lower initial dose (2.5 mg weekly) is intended to reduce GI symptoms; it does not provide effective glycemic control. If changing the day of administration is necessary, allow at least 72 hours between 2 doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24267291-50a0-4efc-98cd-a5840a223299">Weight management, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, chronic</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an adjunct to diet and exercise in patients with a BMI ≥30 kg/m<sup>2</sup> or patients with a BMI ≥27 kg/m<sup>2</sup> and ≥1 weight-associated comorbidity (eg, cardiovascular disease, dyslipidemia, hypertension, obstructive sleep apnea, type 2 diabetes mellitus).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Initial: 2.5 mg once weekly for 4 weeks, then increase to 5 mg once weekly. May further increase dose in 2.5 mg/week increments every 4 weeks, if needed (maximum weekly dose: 15 mg/week).<b> Note:</b> The lower initial dose (2.5 mg weekly) is intended to reduce GI symptoms; it does not provide effective weight loss. If changing the day of administration is necessary, allow at least 72 hours between 2 doses.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> Missed dose should be administered as soon as possible within 4 days; resume usual schedule thereafter. If &gt;4 days have elapsed, skip the missed dose and resume administration at the next scheduled weekly dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56848805"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F56848806"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F56848804"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56990419"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acute kidney injury (AKI), which sometimes requires dialysis, has been reported with glucagon-like peptide-1 (GLP-1) receptor agonists. According to the manufacturer, AKI occurred mostly in patients who experienced nausea, vomiting, diarrhea, or dehydration secondary to GLP-1 receptor agonists.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; exact mechanism is unknown. Pre-renal AKI may occur due to dehydration and volume contraction secondary to GI symptoms (eg, nausea, vomiting, diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; because the mechanism is thought to be related to volume contraction, timing may be dependent on GI symptoms, initiation or dosage adjustment of concurrent medications, and/or comorbid conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Volume contraction (eg, during periods of severe vomiting or diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Co-administration of medications known to result in kidney injury during episodes of dehydration (eg, drugs that inhibit the renin-angiotensin system) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Diabetic retinopathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic retinopathy</b> (DR) was reported with tirzepatide during the SURPASS-2 study, a clinical trial evaluating the safety and efficacy of tirzepatide compared to semaglutide in patients with type 2 diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34170647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34170647'])">Ref</a></span>); patients with a prior history of DR were excluded from this trial. In addition, rapid reductions in HbA<sub>1c</sub> are associated with an early worsening of DR (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9682700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9682700'])">Ref</a></span>). In an analysis of DR complications due to the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, the increased risk of DR was mainly observed in patients with preexisting DR and primarily attributable to the magnitude and rapidity of reduction in HbA<sub>1c</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29178519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29178519'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown. In general, worsening of preexisting DR is a known consequence of rapid improvement of hyperglycemia, especially in patients with uncontrolled diabetes. Although unlikely, a direct toxic effect or potential angiogenic action of tirzepatide has not been ruled out (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28533296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28533296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; clinicians should note that DR is a progressive condition, and the onset of DR complications may vary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting DR</p>
<p style="text-indent:-2em;margin-left:6em;">• In general, the risk of early worsening of DR is increased when intensive treatment is initiated in patient with long-standing poor glycemic control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9682700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9682700'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gallbladder disease</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallbladder disease</b> and biliary tract disease, including <b>biliary colic</b>, <b>cholelithiasis</b>, <b>cholecystitis</b>, cholestasis, cholangitis, and <b>cholecystectomy</b> have been reported with glucagon-like peptide-1 (GLP-1) receptor agonists, including tirzepatide. Resolution of biliary stones following discontinuation has been documented with the GLP-receptor agonist liraglutide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25725635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25725635'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>); not fully understood. Animal studies and in vitro data have demonstrated that GLP-1 enhances the proliferations and functional activity of cholangiocytes, which may result in gallbladder diseases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17631146','lexi-content-ref-18829977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17631146','lexi-content-ref-18829977'])">Ref</a></span>). Some authors have postulated a change in bile acid production and secretion, suppressed secretion of cholecystokinin, decreased gallbladder emptying, prolonged gallbladder refilling, weight loss, or potentially a combination of these factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30137354','lexi-content-ref-31399438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30137354','lexi-content-ref-31399438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; an increased risk was reported following &gt;26 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of treatment (eg, &gt;26 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Substantial or rapid weight loss has been associated with an increased risk with GLP-1 receptor agonists used for weight loss (eg, liraglutide, semaglutide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">GI effects, including <b>abdominal pain</b>, <b>constipation</b>, <b>decreased appetite</b>, <b>diarrhea</b>, <b>dyspepsia</b>, <b>nausea</b>, and <b>vomiting</b>, have been reported with tirzepatide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27981757','lexi-content-ref-25375397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27981757','lexi-content-ref-25375397'])">Ref</a></span>). Symptoms may sometimes be severe. GI effects tend to occur during dose escalation and decrease over time; may result in treatment discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; however, the exact mechanism is not fully understood. May be a result of delayed gastric emptying or activation centers involved in appetite regulation, satiety, and nausea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; nausea, vomiting, and diarrhea are most common soon after initiation (eg, the first 4 weeks of treatment) and during dose escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21975753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21975753'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose; generally greater with higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• In general, rapid titration of GLP-1 receptor agonists is associated with higher risk of GI symptoms</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, immediate <b>hypersensitivity reactions</b>, including <b>anaphylaxis</b> and <b>angioedema</b>, have been reported with glucagon-like peptide-1 (GLP-1) receptor agonists, including tirzepatide. Delayed hypersensitivity reactions have also been documented with GLP-1 receptor agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32301438','lexi-content-ref-31389984','lexi-content-ref-26177483','lexi-content-ref-33144906']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32301438','lexi-content-ref-31389984','lexi-content-ref-26177483','lexi-content-ref-33144906'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic.</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: IgE-antibodies are formed against a drug allergen following initial exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-30350785','lexi-content-ref-25439386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-30350785','lexi-content-ref-25439386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions: T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Rapid; generally occurs within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-31296642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-31296642'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions: Varied; may occur from 1 day to 6 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22727533','lexi-content-ref-30558872','lexi-content-ref-31389984','lexi-content-ref-33144906']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22727533','lexi-content-ref-30558872','lexi-content-ref-31389984','lexi-content-ref-33144906'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between GLP-1 receptor agonists is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32301438','lexi-content-ref-31296642','lexi-content-ref-34860904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32301438','lexi-content-ref-31296642','lexi-content-ref-34860904'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypoglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tirzepatide lowers blood glucose, which may result in <b>hypoglycemia</b> in patients with or without type 2 diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to the mechanism of action; glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concurrent insulin secretagogue (eg, sulfonylurea) and/or insulin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Medullary thyroid carcinoma</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In the early stages of drug development, thyroid C-cell tumors were noted to have developed during animal studies with tirzepatide. It is unknown whether tirzepatide causes thyroid C-cell tumors in humans, as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined. Human cases of medullary thyroid carcinoma (MTC) have been reported with glucagon-like peptide-1 (GLP-1) receptor agonists dulaglutide and liraglutide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Trulicity.1','lexi-content-ref-Victoza.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Trulicity.1','lexi-content-ref-Victoza.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; animal studies have shown dose-dependent and treatment duration-dependent harmful effects in rodents but not primates, thereby indicating that proliferative C-cell effects of GLP-1 receptor agonists may be rodent-specific. Humans have far fewer C-cells than rodents, and expression of the GLP-1 receptor in human C-cells is very low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20203154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20203154'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with a personal or family history of MTC or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2) may be at an increased risk</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pancreatitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>acute pancreatitis</b> (including hemorrhagic pancreatitis and necrotizing pancreatitis with some fatalities), chronic pancreatitis, and pancreatic adenocarcinoma have been reported with use of incretin-based therapies (eg, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide-1 [GLP-1] receptor agonists) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010561','lexi-content-ref-21334333','lexi-content-ref-FDA.1','lexi-content-ref-24702687','lexi-content-ref-23440284']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010561','lexi-content-ref-21334333','lexi-content-ref-FDA.1','lexi-content-ref-24702687','lexi-content-ref-23440284'])">Ref</a></span>). In clinical trials, acute pancreatitis was observed with tirzepatide.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Causality has not been firmly established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24571751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24571751'])">Ref</a></span>). GLP-1 receptor agonists directly stimulate GLP-1 receptors in pancreatic islet beta cells and exocrine duct cells which may cause an overgrowth of the cells that cover the smaller ducts, thereby resulting in hyperplasia, increased pancreatic weight, duct occlusion, back pressure, and subsequent acute or chronic pancreatic inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27883260','lexi-content-ref-25633664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27883260','lexi-content-ref-25633664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with a prior history of pancreatitis may be at an increased risk for acute pancreatitis</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with acute pancreatitis due to any cause are at an increased risk for progression to recurrent acute pancreatitis and then to chronic pancreatitis; patients with chronic pancreatitis are at an increased risk for pancreatic cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23622135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23622135'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Risk factors for pancreatitis due to any cause include, but are not limited to, hypertriglyceridemia, cholelithiasis, alcohol use, and obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23622135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23622135'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56839692"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (6% to 17%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 1</a>)</span><span class="table-link" style="display:none;">Constipation</span>, decreased appetite (5% to 11%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Appetite table link" class="lexi-table-link" data-table-id="lexi-content-decreased-appetite" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-appetite')">table 2</a>)</span><span class="table-link" style="display:none;">Decreased Appetite</span>, diarrhea (12% to 23%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 3</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, nausea (12% to 29%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 4</a>)</span><span class="table-link" style="display:none;">Nausea</span>, vomiting (5% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 5</a>)</span><span class="table-link" style="display:none;">Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">630</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">948</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">941</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">237</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Appetite" frame="border" id="lexi-content-decreased-appetite" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Decreased Appetite</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">237</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">941</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">948</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">630</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">237</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">948</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">941</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">630</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">237</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">941</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">948</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">630</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">237</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (51% to 65%; neutralizing: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (1% to 2%), sinus tachycardia (5% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Sinus Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-sinus-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sinus-tachycardia')">table 6</a>)</span><span class="table-link" style="display:none;">Sinus Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sinus Tachycardia" frame="border" id="lexi-content-sinus-tachycardia" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Sinus Tachycardia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Increase from baseline in heart rate of ≥15 beats per minute</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Increase from baseline in heart rate of ≥15 beats per minute</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">237</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Increase from baseline in heart rate of ≥15 beats per minute</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (4% to 5%; more common in females)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (≤4%)<span class="lexi-table-link-container"> (<a aria-label="Hypoglycemia table link" class="lexi-table-link" data-table-id="lexi-content-hypoglycemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypoglycemia')">table 7</a>)</span><span class="table-link" style="display:none;">Hypoglycemia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypoglycemia" frame="border" id="lexi-content-hypoglycemia" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Hypoglycemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Patients with type 2 diabetes mellitus and BMI ≥27 kg/m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plasma glucose &lt;54 mg/dL. Rates increased with combination hypoglycemia agents.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Patients with obesity/overweight (without type 2 diabetes mellitus)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plasma glucose &lt;54 mg/dL.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (3% to 4%), abdominal pain (5% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Abdominal Pain table link" class="lexi-table-link" data-table-id="lexi-content-abdominal-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abdominal-pain')">table 8</a>)</span><span class="table-link" style="display:none;">Abdominal Pain</span>, dyspepsia (5% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Dyspepsia table link" class="lexi-table-link" data-table-id="lexi-content-dyspepsia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dyspepsia')">table 9</a>)</span><span class="table-link" style="display:none;">Dyspepsia</span>, eructation (3% to 5%), flatulence (1% to 4%), gallbladder disease (acute; including biliary colic, cholecystectomy [0.2%]<span class="lexi-table-link-container"> (<a aria-label="Cholecystectomy table link" class="lexi-table-link" data-table-id="lexi-content-cholecystectomy" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cholecystectomy')">table 10</a>)</span><span class="table-link" style="display:none;">Cholecystectomy</span>, cholecystitis [0.2%]<span class="lexi-table-link-container"> (<a aria-label="Cholecystitis table link" class="lexi-table-link" data-table-id="lexi-content-cholecystitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cholecystitis')">table 11</a>)</span><span class="table-link" style="display:none;">Cholecystitis</span>, and cholelithiasis [≤1%]<span class="lexi-table-link-container"> (<a aria-label="Cholelithiasis table link" class="lexi-table-link" data-table-id="lexi-content-cholelithiasis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cholelithiasis')">table 12</a>)</span><span class="table-link" style="display:none;">Cholelithiasis</span>), gastroesophageal reflux disease (2% to 5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abdominal Pain" frame="border" id="lexi-content-abdominal-pain" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Abdominal Pain</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">941</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">948</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">630</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">237</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cholecystectomy" frame="border" id="lexi-content-cholecystectomy" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Cholecystectomy</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cholecystitis" frame="border" id="lexi-content-cholecystitis" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction:</b>
<b>Cholecystitis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cholelithiasis" frame="border" id="lexi-content-cholelithiasis" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Cholelithiasis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">718</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dyspepsia" frame="border" id="lexi-content-dyspepsia" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Dyspepsia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">941</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">948</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">630</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">237</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2% to 5%; including severe hypersensitivity reaction [&lt;1%])<span class="lexi-table-link-container"> (<a aria-label="Hypersensitivity Reaction table link" class="lexi-table-link" data-table-id="lexi-content-hypersensitivity-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypersensitivity-reaction')">table 13</a>)</span><span class="table-link" style="display:none;">Hypersensitivity Reaction</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypersensitivity Reaction" frame="border" id="lexi-content-hypersensitivity-reaction" rules="all">
<caption style="text-align:center;">
<b>Tirzepatide: Adverse Reaction: Hypersensitivity Reaction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirzepatide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">941</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">948</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once weekly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">630</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delayed reaction</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obesity or overweight</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate reaction</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">718</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (4% to 5%), fatigue (5% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Acute pancreatitis, increased serum amylase, increase serum lipase</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetic retinopathy (Frias 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Aleman Espino 2023)</p></div>
<div class="block coi drugH1Div" id="F56830412"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serious hypersensitivity to tirzepatide or any component of the formulation; serious hypersensitivity reactions including anaphylaxis and angioedema have been reported; a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Breastfeeding; pregnancy.</p></div>
<div class="block war drugH1Div" id="F56848784"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">- Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy, and closely monitor the patient for the duration of therapy; acute and chronic kidney failure exacerbation may occur. A majority of cases occurred in patients with nausea, vomiting, diarrhea, and/or dehydration. Nausea is common and fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">- Excessive glucagon-like peptide-1 exposure: Closely monitor for efficacy and assess for signs and symptoms of pancreatitis if therapy is initiated after surgery; gastric bypass and sleeve gastrectomy (but not gastric band) significantly increase endogenous postprandial GLP-1 concentrations (Korner 2009; Peterli 2012). Administration of exogenous GLP-1 receptor agonists may be redundant to surgery effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed gastric emptying: Tirzepatide slows gastric emptying, which may alter the absorption of other medications. Monitor narrow therapeutic index medications for increased or decreased response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Diabetes mellitus: Do not use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; not a substitute for insulin.</p></div>
<div class="block foc drugH1Div" id="F56874965"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zepbound: 2.5 mg/0.5 mL (0.5 mL); 5 mg/0.5 mL (0.5 mL); 7.5 mg/0.5 mL (0.5 mL); 10 mg/0.5 mL (0.5 mL); 12.5 mg/0.5 mL (0.5 mL); 15 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mounjaro: 2.5 mg/0.5 mL (0.5 mL); 5 mg/0.5 mL (0.5 mL); 7.5 mg/0.5 mL (0.5 mL); 10 mg/0.5 mL (0.5 mL); 12.5 mg/0.5 mL (0.5 mL); 15 mg/0.5 mL (0.5 mL)</p></div>
<div class="block geq drugH1Div" id="F56874963"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57055666"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Zepbound Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/0.5 mL (per 0.5 mL): $317.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/0.5 mL (per 0.5 mL): $317.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg/0.5 mL (per 0.5 mL): $317.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/0.5 mL (per 0.5 mL): $317.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/0.5 mL (per 0.5 mL): $317.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg/0.5 mL (per 0.5 mL): $317.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Mounjaro Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/0.5 mL (per 0.5 mL): $320.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/0.5 mL (per 0.5 mL): $320.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg/0.5 mL (per 0.5 mL): $320.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/0.5 mL (per 0.5 mL): $320.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/0.5 mL (per 0.5 mL): $320.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg/0.5 mL (per 0.5 mL): $320.72</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F58872667"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mounjaro: 2.5 mg/0.5 mL (0.5 mL); 5 mg/0.5 mL (0.5 mL); 7.5 mg/0.5 mL (0.5 mL); 10 mg/0.5 mL (0.5 mL); 12.5 mg/0.5 mL (0.5 mL); 15 mg/0.5 mL (0.5 mL)</p></div>
<div class="block adm drugH1Div" id="F56848807"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Administer by SUBQ injection into the abdomen, thigh, or upper arm at any time of day on the same day each week, with or without food. If changing the day of administration is necessary, allow ≥72 hours between 2 doses. Rotate injection sites with each dose. Do not mix with other injectable products (eg, insulin); administer as separate injections. Avoid adjacent injections if administering other agents in the same area of the body. Solution should be clear and colorless to slightly yellow; do not use if particulate matter or discoloration are seen. Tirzepatide is a single-dose device that <b>does not</b> require priming before injection.</p></div>
<div class="block meg drugH1Div" id="F56848776"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:-2em;margin-left:2em;">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Mounjaro: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F215866s002s006lbl.pdf%23page%3D20&amp;token=tI6TndxKyn6pOLkipUdlwY0EFEu2IVcLOIQiAuyiOTXx4jVzbgbSctMb5Sq85l%2F8k6WrlMFPd6DoNjqSYmlZE5qj3y2a5HY8FGaXxBWGN%2FMCHfMp9M%2FKxvp2U%2BItl2CK&amp;TOPIC_ID=138675" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866s002s006lbl.pdf#page=20</a></p></div>
<div class="block use drugH1Div" id="F56830411"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Type 2 diabetes mellitus, treatment (Mounjaro):</b> As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Has not been studied in patients with a history of pancreatitis; not indicated for use in patients with type 1 diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, chronic</b>
<b>(Zepbound):</b> As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial BMI of ≥30 kg/m<sup>2</sup> (obesity) or ≥27 kg/m<sup>2</sup> (overweight) in the presence of ≥1 weight-related comorbid condition (eg, cardiovascular disease, dyslipidemia, hypertension, obstructive sleep apnea, type 2 diabetes mellitus).<b></b></p></div>
<div class="block mst drugH1Div" id="F56848775"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Tirzepatide may be confused with teriparatide, tolazamide.</p>
<p style="text-indent:0em;margin-left:2em;">Mounjaro may be confused with Monjuvi.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56834990"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56834987"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: Tirzepatide may enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: Tirzepatide may decrease the serum concentration of Hormonal Contraceptives.  Management: Patients using oral hormonal contraceptives should switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation of tirzepatide and for 4 weeks after each dose escalation of tirzepatide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Insulins.  Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglitinides: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Meglitinides.  Management: Consider meglitinide dose reductions when used in combination with glucagon-like peptide-1 agonists, particularly when also used with basal insulin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Semaglutide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Tirzepatide may increase the serum concentration of Warfarin. Tirzepatide may decrease the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56848778"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Agents other than tirzepatide are currently recommended for patients with type 2 diabetes mellitus planning to become pregnant (ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Obesity increases the risk of infertility. Optimal weight control prior to conception improves pregnancy outcomes; however, medications for weight loss are not recommended prior to pregnancy due to safety issues and adverse events. Weight loss medications should be discontinued prior to conception (ACOG 2021; Wharton 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Tirzepatide may decrease the efficacy of oral hormonal contraception due to changes in gastric emptying; contraceptives administered by a nonoral route are not affected. Because the changes in gastric emptying are largest following the first dose, patients using an oral contraceptive should add a barrier method for 4 weeks after starting tirzepatide treatment and for 4 weeks after each dose increase. Alternately, patients can be switched to nonoral contraceptive methods.</p>
<p style="text-indent:0em;margin-top:2em;">Consult drug interactions database for more detailed information specific to use of tirzepatide and specific contraceptives.</p></div>
<div class="block pri drugH1Div" id="F56848779"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to tirzepatide may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia (ACOG 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than tirzepatide are currently recommended to treat diabetes mellitus in pregnancy (ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of adverse maternal and fetal events is associated with obesity; however, moderate gestational weight gain based on prepregnancy BMI is required for positive fetal outcomes in all pregnancies, including patients who are overweight or obese. Therefore, medications for weight loss therapy are not recommended during pregnancy (ACOG 2021; Wharton 2020). Patients should discontinue tirzepatide once pregnancy is recognized.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to tirzepatide is ongoing. Health care providers are encouraged to enroll patients exposed to Zepbound during pregnancy in the registry (1-800-545-5979); patients may also enroll themselves.</p></div>
<div class="block brc drugH1Div" id="F56848780"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tirzepatide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F56848810"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Plasma glucose; GI adverse reactions (eg, nausea, vomiting, diarrhea); kidney function (at baseline and following dose increases in patients with kidney impairment reporting severe GI adverse reactions); signs/symptoms of pancreatitis (eg, persistent severe abdominal pain, which may radiate to the back and that may or may not be accompanied by vomiting); signs/symptoms of gallbladder disease; worsening of diabetic retinopathy (particularly in those with a prior history of the disease); emergence of worsening depression, suicidal thoughts/behavior, changes in behavior; heart rate; body weight (when used for chronic weight management).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HbA<sub>1c</sub>:</i> Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F56848809"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults (AACE [Samson 2023], ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note:</b> Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F56848788"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, slows gastric emptying, and decreases food intake.</p></div>
<div class="block phk drugH1Div" id="F56848789"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: ~9.7 to 10.3 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99% to plasma albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: By proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety, and amide hydrolysis.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 80%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 8 to 72 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine and feces (as metabolites).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 0.056 to 0.061 L/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58847638"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Mounjaro</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37720126">
<a name="37720126"></a>Aleman Espino A, Aleman Espino E, Aleman Oliva C, Monteagudo H, Frontela O. An incidental finding of a glucagon-like peptide 1 (GLP-1)-induced acute kidney injury: a case report. <i>Cureus</i>. 2023;15(9):e45261. doi:10.7759/cureus.45261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/37720126/pubmed" id="37720126" target="_blank">37720126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23010561">
<a name="23010561"></a>Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. <i>Diabetes Res Clin Pract</i>. 2012;98(2):271-284. doi:10.1016/j.diabres.2012.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/23010561/pubmed" id="23010561" target="_blank">23010561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 201: pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34011890">
<a name="34011890"></a>American College of Obstetricians and Gynecologists (ACOG). Obesity in pregnancy: ACOG practice bulletin no. 230. <i>Obstet Gynecol</i>. 2021;137(6):e128-e144. doi:10.1097/AOG.0000000000004395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/34011890/pubmed" id="34011890" target="_blank">34011890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023.<i> Diabetes Care.</i> 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22727533">
<a name="22727533"></a>Besemer F, Verschoor AJ, Diamant M, Hoogma RP. Vesiculopustular dermatosis: an uncommon side-effect of liraglutide? <i>J Diabetes Complications</i>. 2012;26(5):458-459. doi:10.1016/j.jdiacomp.2012.05.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/22727533/pubmed" id="22727533" target="_blank">22727533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20203154">
<a name="20203154"></a>Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. <i>Endocrinology</i>. 2010;151(4):1473-1486. doi:10.1210/en.2009-1272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/20203154/pubmed" id="20203154" target="_blank">20203154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32301438">
<a name="32301438"></a>Carvallo A, Silva C, Gastaminza G, D'Amelio CM. Delayed hypersensitivity reaction to liraglutide: a case report. <i>J Investig Allergol Clin Immunol</i>. 2020;30(5):367-369. doi:10.18176/jiaci.0521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/32301438/pubmed" id="32301438" target="_blank">32301438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31389984">
<a name="31389984"></a>Cogen AL, Desai K, Elder D, Rosenbach M. Acute photodistributed exanthematous pustulosis associated with liraglutide treatment. <i>JAMA Dermatol</i>. 2019;155(10):1198-1200. doi:10.1001/jamadermatol.2019.1893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/31389984/pubmed" id="31389984" target="_blank">31389984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9682700">
<a name="9682700"></a>Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. <i>Arch Ophthalmol</i>. 1998;116(7):874-886. doi:10.1001/archopht.116.7.874<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/9682700/pubmed" id="9682700" target="_blank">9682700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24571751">
<a name="24571751"></a>Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. <i>N Engl J Med</i>. 2014;370(9):794-797. doi:10.1056/NEJMp1314078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/24571751/pubmed" id="24571751" target="_blank">24571751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21334333">
<a name="21334333"></a>Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. <i>Gastroenterology</i>. 2011;141(1):150-156. doi:10.1053/j.gastro.2011.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/21334333/pubmed" id="21334333" target="_blank">21334333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA drug safety communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Food and Drug Administration. Updated March 14, 2013. Accessed July 20, 2022. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26177483">
<a name="26177483"></a>Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. <i>Rev Diabet Stud</i>. 2014;11(3-4):202-230. doi:10.1900/RDS.2014.11.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/26177483/pubmed" id="26177483" target="_blank">26177483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34170647">
<a name="34170647"></a>Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. <i>N Engl J Med</i>. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/34170647/pubmed" id="34170647" target="_blank">34170647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - <i>2020 executive summary</i>. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30137354">
<a name="30137354"></a>Gether IM, Nexøe-Larsen C, Knop FK. New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs. <i>J Clin Endocrinol Metab</i>. 2019;104(7):2463-2472. doi:10.1210/jc.2018-01008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/30137354/pubmed" id="30137354" target="_blank">30137354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24702687">
<a name="24702687"></a>Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. <i>Diabetes Obes Metab</i>. 2014;16(11):1041-1047. doi:10.1111/dom.12297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/24702687/pubmed" id="24702687" target="_blank">24702687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35344001">
<a name="35344001"></a>He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. <i>JAMA Intern Med</i>. 2022;182(5):513-519. doi:10.1001/jamainternmed.2022.0338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/35344001/pubmed" id="35344001" target="_blank">35344001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27981757">
<a name="27981757"></a>Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. <i>Diabetes Obes Metab</i>. 2017;19(4):524-536. doi:10.1111/dom.12849<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/27981757/pubmed" id="27981757" target="_blank">27981757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(suppl 4):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27883260">
<a name="27883260"></a>Knapen LM, de Jong RG, Driessen JH, et al. Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study. <i>Diabetes Obes Metab</i>. 2017;19(3):401-411. doi:10.1111/dom.12833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/27883260/pubmed" id="27883260" target="_blank">27883260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25725635">
<a name="25725635"></a>Korkmaz H, Araz M, Alkan S, Akarsu E. Liraglutide-related cholelithiasis. <i>Aging Clin Exp Res</i>. 2015;27(5):751-753. doi:10.1007/s40520-015-0335-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/25725635/pubmed" id="25725635" target="_blank">25725635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond)</i>. 2009;33(7):786-795. doi:10.1038/ijo.2009.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol</i>
<i>Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18829977">
<a name="18829977"></a>Marzioni M, Alpini G, Saccomanno S, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. <i>Gut</i>. 2009;58(7):990-997. doi:10.1136/gut.2008.150870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/18829977/pubmed" id="18829977" target="_blank">18829977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17631146">
<a name="17631146"></a>Marzioni M, Alpini G, Saccomanno S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. <i>Gastroenterology</i>. 2007;133(1):244-255. doi:10.1053/j.gastro.2007.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/17631146/pubmed" id="17631146" target="_blank">17631146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mounjaro.1">
<a name="Mounjaro.1"></a>Mounjaro (tirzepatide) [prescribing information]. Indianapolis, IN: Lilly USA LLC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mounjaro.1">
<a name="Mounjaro.1"></a>Mounjaro (tirzepatide) [prescribing information]. Indianapolis, IN: Lilly USA LLC; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mounjaro.2">
<a name="Mounjaro.2"></a>Mounjaro (tirzepatide) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31399438">
<a name="31399438"></a>Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. <i>Diabetes Care</i>. 2019;42(10):1912-1920. doi:10.2337/dc19-0415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/31399438/pubmed" id="31399438" target="_blank">31399438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30350785">
<a name="30350785"></a>Ornelas C, Caiado J, Lopes A, Pereira Dos Santos MC, Pereira Barbosa M. Anaphylaxis to long-acting release exenatide. <i>J Investig Allergol Clin Immunol</i>. 2018;28(5):332-334. doi:10.18176/jiaci.0274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/30350785/pubmed" id="30350785" target="_blank">30350785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25439386">
<a name="25439386"></a>Pérez E, Martínez-Tadeo J, Callero A, Hernández G, Rodríguez-Plata E, García-Robaina JC. A case report of allergy to exenatide. <i>J Allergy Clin Immunol Pract</i>. 2014;2(6):822-823. doi:10.1016/j.jaip.2014.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/25439386/pubmed" id="25439386" target="_blank">25439386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi:10.1007/s11695-012-0622-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144906">
<a name="33144906"></a>Rzepka PV, Kaffenberger JA. A case of morbilliform drug eruption to dulaglutide. <i>J Clin Aesthet Dermatol</i>. 2020;13(4):13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/33144906/pubmed" id="33144906" target="_blank">33144906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31296642">
<a name="31296642"></a>Shamriz O, NaserEddin A, Mosenzon O, Sviri S, Tal Y. Allergic reaction to exenatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists. <i>Diabetes Care</i>. 2019;42(9):e141-e142. doi:10.2337/dc19-0720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/31296642/pubmed" id="31296642" target="_blank">31296642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21975753">
<a name="21975753"></a>Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. <i>Cochrane Database Syst Rev</i>. 2011;2011(10):CD006423. doi:10.1002/14651858.CD006423.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/21975753/pubmed" id="21975753" target="_blank">21975753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28533296">
<a name="28533296"></a>Simó R, Hernández C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? <i>Diabetes</i>. 2017;66(6):1453-1460. doi:10.2337/db16-1364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/28533296/pubmed" id="28533296" target="_blank">28533296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23440284">
<a name="23440284"></a>Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. <i>JAMA Intern Med</i>. 2013;173(7):534-539. doi:10.1001/jamainternmed.2013.2720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/23440284/pubmed" id="23440284" target="_blank">23440284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34860904">
<a name="34860904"></a>Steveling EH, Winzeler B, Bircher AJ. Systemic allergic reaction to the GLP-1 receptor agonist exenatide. <i>J Pharm Technol</i>. 2014;30(5):182-186. doi:10.1177/8755122514539462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/34860904/pubmed" id="34860904" target="_blank">34860904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25375397">
<a name="25375397"></a>Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. <i>Diabetes Technol Ther</i>. 2015;17(1):35-42. doi:10.1089/dia.2014.0188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/25375397/pubmed" id="25375397" target="_blank">25375397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25633664">
<a name="25633664"></a>Thomsen RW, Pedersen L, Møller N, Kahlert J, Beck-Nielsen H, Sørensen HT. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. <i>Diabetes Care</i>. 2015;38(6):1089-1098. doi:10.2337/dc13-2983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/25633664/pubmed" id="25633664" target="_blank">25633664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trulicity.1">
<a name="Trulicity.1"></a>Trulicity (dulaglutide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Victoza.1">
<a name="Victoza.1"></a>Victoza (liraglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29178519">
<a name="29178519"></a>Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes Obes Metab</i>. 2018;20(4):889-897. doi:10.1111/dom.13172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/29178519/pubmed" id="29178519" target="_blank">29178519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32753461">
<a name="32753461"></a>Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. <i>CMAJ</i>. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/32753461/pubmed" id="32753461" target="_blank">32753461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23622135">
<a name="23622135"></a>Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. <i>Gastroenterology</i>. 2013;144(6):1252-1261. doi:10.1053/j.gastro.2013.01.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirzepatide-drug-information/abstract-text/23622135/pubmed" id="23622135" target="_blank">23622135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zepbound.1">
<a name="Zepbound.1"></a>Zepbound (tirzepatide) [prescribing information]. Indianapolis, IN: Lilly USA LLC; November 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 138675 Version 68.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
